Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Pembrolizumab in Anaplastic or Poorly Differentiated Thyroid Carcinoma
DRKS00013336Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in poorly differentiated thyroid carcinoma (PDTC), sponsored by Universitätsklinikum Freiburg. Started May 2019; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
poorly differentiated thyroid carcinoma (PDTC)
Beyond the preview
Go deeper on DRKS00013336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00013336.